文献速递慢性肾脏病

CKD中两种代谢组学平台的变异性

Variability of Two Metabolomic Platforms in CKD.
PubMed 文献 · Clin J Am Soc Nephrol · 2018-12-20

该研究纳入49例CKD患者(eGFR<60 ml/min per 1.73 m2和/或蛋白尿≥1 g),在两次访视中采集血浆,其中20份样本作为盲法重复检测,并在Metabolon和Broad Institute两个非靶向平台进行代谢组学分析。结果显示两个平台已知代谢物的技术变异系数较低,重叠代谢物一致性极佳,但多数代谢物存在显著个体内变异并与eGFR相关。

要点

  • 两个非靶向平台已知代谢物盲法重复的中位CV分别为14.6%(Metabolon)和6.3%(Broad Institute)。
  • 381种已知代谢物在两平台共享,中位相关系数为0.89。
  • 许多代谢物与eGFR负相关(P<0.05),Metabolon和Broad Institute已知代谢物分别占35.7%和18.9%。

核心结论

  • 非靶向代谢组学可定量超过1000种分析物,技术CV较低,两个平台重叠代谢物一致性极佳;但多数代谢物存在显著个体内变异并与eGFR相关。

研究设计与样本

  • 研究纳入49例CKD患者(eGFR<60 ml/min per 1.73 m2和/或蛋白尿≥1 g),来自两次研究访视,其中20份样本作为盲法重复检测,并在Metabolon和Broad Institute两个非靶向平台进行代谢组学分析。

主要发现

  • Metabolon平台报告837种已知代谢物和483种未命名化合物(从44,953个未知离子特征中选出);Broad Institute平台报告594种已知代谢物和26,106个未知离子特征。
  • 已知代谢物盲法重复的中位CV分别为14.6%(Metabolon)和6.3%(Broad Institute);未命名化合物为18.9%(Metabolon),未知离子特征为24.5%(Broad Institute)。
  • 已知代谢物日间变异的中位CV分别为29.0%(Metabolon)和24.9%(Broad Institute);未命名化合物为41.8%(Metabolon),未知离子特征为40.9%(Broad Institute)。
  • 两平台共享381种已知代谢物,中位相关系数为0.89。
  • 许多代谢物与eGFR负相关(P<0.05),包括35.7%(Metabolon)和18.9%(Broad Institute)的已知代谢物。

临床怎么用

  • 在CKD生物标志物发现中,应关注代谢物个体内变异及与eGFR的相关性,并注意平台间技术CV差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Nontargeted metabolomics can measure thousands of low-molecular-weight biochemicals, but important gaps limit its utility for biomarker discovery in CKD. These include the need to characterize technical and intraperson analyte variation, to pool data across platforms, and to outline analyte relationships with eGFR. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Plasma samples from 49 individuals with CKD (eGFR<60 ml/min per 1.73 m2 and/or ≥1 g proteinuria) were examined from two study visits; 20 samples were repeated as blind replicates. To enable comparison across two nontargeted platforms, samples were profiled at Metabolon and the Broad Institute. RESULTS: The Metabolon platform reported 837 known metabolites and 483 unnamed compounds (selected from 44,953 unknown ion features). The Broad Institute platform reported 594 known metabolites and 26,106 unknown ion features. Median coefficients of variation (CVs) across blind replicates were 14.6% (Metabolon) and 6.3% (Broad Institute) for known metabolites, and 18.9% for (Metabolon) unnamed compounds and 24.5% for (Broad Institute) unknown ion features. Median CVs for day-to-day variability were 29.0% (Metabolon) and 24.9% (Broad Institute) for known metabolites, and 41.8% for (Metabolon) unnamed compounds and 40.9% for (Broad Institute) unknown ion features. A total of 381 known metabolites were shared across platforms (median correlation 0.89). Many metabolites were negatively correlated with eGFR at P<0.05, including 35.7% (Metabolon) and 18.9% (Broad Institute) of known metabolites. CONCLUSIONS: Nontargeted metabolomics quantifies >1000 analytes with low technical CVs, and agreement for overlapping metabolites across two leading platforms is excellent. Many metabolites demonstrate substantial intraperson variation and correlation with eGFR.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Rhee EP, Waikar SS, Rebholz CM, et al. Variability of Two Metabolomic Platforms in CKD. Clin J Am Soc Nephrol. 2018. PMID: 30573658. doi:10.2215/CJN.07070618

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。